Results 151 to 160 of about 395,238 (233)

Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial. [PDF]

Vaccines (Basel), 2023
Baker B, Bermingham IM, Leelasena I, Hickling J, Young PR, Muller DA, Forster AH.   +6 more
europepmc   +1 more source

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. [PDF]

Viruses
Rao SN, Ambike D, Patil M, Mankar SV, Verma N, Hanumante N, Sarangi L, Mitra M, Preeti G, Deshmukh BJ, Nanoti G, Faridi MMA, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Kunnathamman R, Elaiyaraja M, Dutta T, Mahajan M, Desai S.   +21 more
europepmc   +1 more source

Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis? [PDF]

Sudan J Paediatr, 2022
Shrivastava J, Narang M, Gomber S.
europepmc   +1 more source

A Comparative Prospective Study to Assess Efficacy of Intralesional MMR (Measles, Mumps, Rubella) Vaccine and Intralesional Vitamin D3 in Treatment of Nongenital Warts. [PDF]

Health Sci Rep
Baaniya B, Marahatta S, Dahal R, Shah N.
europepmc   +1 more source

Intralesional Measles, Mumps and Rubella Vaccine versus Formic Acid Puncture in the Treatment of Common Warts: A Prospective Randomised Study.

Indian J Dermatol, 2023
D'Souza MJ, Hundi GK, Dandekeri S, Jayaraman J.   +3 more
europepmc   +1 more source

Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases. [PDF]

Oman Med J, 2022
Al-Qassabi AM, Al Kindi A.
europepmc   +1 more source

Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins. [PDF]

J Infect Dis
Chen MH, Perelygina L, Hao L, Beard RS, Lackner C, Farcet MR, Karbiener M, Icenogle J, Kreil TR.   +8 more
europepmc   +1 more source

The Oncogenic Human Papillomavirus Involvement as a Risk Factor of Measles, Mumps, and Rubella Vaccine Immunotherapy Failure in Anogenital Warts. [PDF]

Int Med Case Rep J
Achdiat PA, Ismiranty D, Hindritiani R, Rizqandaru T, Usman HA, Maharani RH.   +5 more
europepmc   +1 more source

A Comparative Analysis of Efficacy of Intralesional Mumps-Measles-Rubella Vaccine Versus 5-Fluorouracil in the Treatment of Palmoplantar Warts. [PDF]

Indian Dermatol Online J, 2022
Sunny AS, Doshi BR.
europepmc   +1 more source

Measles & rubella move fast

Measles & Rubella Initiative : a global partnership to stop mealses ...

core